3 Indian Stocks Trading Below Fair Value With Strong Cash Flow Backing

Eurozone manufacturing just hit a four year high, with Germany’s factories taking the lead. That kind of broadening pickup in goods production can shine a light on companies that already generate solid cash flows yet have share prices that still lag behind fair value. For investors who care about price discipline, this article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that are worth a closer look.

The three stocks profiled below are just a sample. The full screen highlights 26 more companies with similarly interesting cash flow stories that are not covered here but may deserve your attention. To identify and analyze the highest conviction ideas from this wider group, head straight to the Undervalued Stocks Based On Cash Flows screener.

Overview: Entero Healthcare Solutions runs a large-scale distribution and logistics platform for pharmaceuticals, medical devices and hospital consumables across India, supplying pharmacies, hospitals and clinics and also selling private-label Entero Surgicals products. Its core role in moving healthcare products from manufacturers to end users on recurring contracts is a direct link to the Undervalued Stocks Based On Cash Flows theme.

Operations: Entero Healthcare Solutions generates all of its ₹71.3b in revenue from trading pharmaceutical and surgical products in India.

Market Cap: ₹61.96b

Entero Healthcare Solutions gives you exposure to India’s need for medicines and medical devices through a distribution platform that produces recurring, contract based cash flows. Yet the stock still screens as significantly below estimated fair value on a DCF basis. Revenue of ₹66.1b and full year net income of ₹1.15b, alongside recent quarterly earnings that were higher than the prior year, indicate that the cash generation story is already taking shape rather than sitting purely in forecasts. At the same time, thin margins, reliance on acquisitions and rising digital competition mean execution on efficiency, working capital and tech adoption really matters. For investors who want that combination of cash-flow potential and genuine execution risk, Entero is worth a closer look.

Entero Healthcare Solutions looks like a cash engine whose thin margins and acquisition push may be masking its true worth. Get the DCF valuation analysis for Entero Healthcare Solutions to see where the valuation gap could close or widen next.

Build your own cash flow shortlist

Entero Healthcare Solutions and the other two stocks in this list were all surfaced through a single screener, but the real edge comes when you shape the filters yourself. Use our flexible Screener to blend valuation, growth and balance sheet checks, or tap into pre-built themes through our curated Investing Ideas.

Overview: S H Kelkar manufactures and supplies fragrances, flavors and aroma ingredients for everyday consumer products, selling branded and custom solutions under labels such as SHK, Cobra, Keva and CFF to FMCG customers in India and overseas. This recurring, high margin B2B fragrances and flavors engine is the clearest link to the Undervalued Stocks Based On Cash Flows theme, even though the company also has smaller activities in research and custom synthesis.

Operations: S H Kelkar generates most of its revenue from fragrances at about ₹36.1b, with a smaller contribution of roughly ₹3.4b from flavors, before segment adjustments.

Market Cap: ₹21.8b

S H Kelkar provides exposure to steady, contract based cash flows that come from supplying essential fragrances and flavors to large consumer brands, while the stock is flagged as trading well below estimated DCF fair value. Recent Q1 FY2027 results showed higher revenue and net income alongside better EPS. This points to improving cash generation even as net margins have recently come under pressure. At the same time, weaker interest cover, higher reliance on external funding and the impact of raw material costs keep financial risk on the table. For investors who want recurring B2B cash flows with a clear value signal and who are willing to track margin recovery and balance sheet discipline closely, S H Kelkar may merit further research.

S H Kelkar’s cash flows and recent Q1 FY2027 earnings strength suggest the story may be decoupling from the share price. Read the 2 key rewards and 4 important warning signs (1 is major!) to see what the balance between opportunity and pressure really looks like.

Overview: Mangalore Refinery and Petrochemicals runs a large refinery in India that turns imported crude oil into fuels like diesel, petrol, LPG and naphtha, along with smaller volumes of petrochemicals such as polypropylene, and sells these products domestically and through exports. This refining activity is the main link to the Undervalued Stocks Based On Cash Flows theme, because it can generate relatively steady downstream cash flows from high volume fuel sales, even though petrochemicals remain a smaller, diversifying line.

Operations: Mangalore Refinery and Petrochemicals generates all of its revenue of about ₹1,095.6b from its downstream petroleum segment.

Market Cap: ₹309.9b

Mangalore Refinery and Petrochemicals combines a large, cash focused refining operation with a valuation that screens as attractive on SWS’s DCF and P/E checks. This is why value driven investors may want it on their radar. The refinery’s throughput and fuel exports are already reflected in healthier earnings. However, debt coverage by operating cash flow, exposure to imported crude and long term pressure from alternative energy keep the risks significant. At the same time, recent profitability, high but debt influenced ROE and ongoing cost and throughput efforts indicate that the cash flow profile is still evolving. For investors seeking a refinery driven cash flow exposure with both potential upside and notable balance sheet considerations, MRPL may warrant closer study.

Mangalore Refinery and Petrochemicals appears to be an earnings story that may not be fully reflected in the share price yet, with debt and crude exposure shaping the real risk reward picture. Read the analysis report for Mangalore Refinery and Petrochemicals

Seeking Fresh Alternatives Before Others Catch On

Some of the most compelling breakouts start quietly, while attention sits elsewhere and prices have not fully caught the momentum. Before these ideas stop flying under the radar for now, consider reviewing them.

• Spot companies turning steady cash into rising dividends by scanning the curated 426 dividend fortresses before yields get compressed and income opportunities start dropping.
• Track early movers in robotics and automation as capital flows toward productivity plays by running the hand picked 37 robotics and automation stocks while the crowd is still distracted.
• Review potential infrastructure momentum by checking the carefully filtered 39 power grid technology and infrastructure stocks before interest in grid upgrades changes the landscape for quality picks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com